---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-23-008652"
form_type: "8-K"
ticker: "VYGR"
cik: "0001640266"
company_name: "Voyager Therapeutics, Inc."
filed_at: "2023-05-09T23:59:59+00:00"
generated_at: "2026-06-15T09:17:11.501483+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Voyager Therapeutics Q1 net income $124M on $150.5M collaboration revenue; cash $273.3M

## Summary
- Net income of $124.0M in Q1 2023 vs net loss of $21.3M in Q1 2022; collaboration revenue $150.5M (vs $0.7M).
- Cash, cash equivalents and marketable securities $273.3M as of March 31, 2023; plus $25M Novartis option payment received after quarter.
- Neurocrine Biosciences strategic collaboration: $175M upfront, up to $1.5B development milestones, $2.7B commercial milestones.
- Novartis exercised options for novel TRACER capsids: $25M payment, up to $600M milestones and royalties.
- Anti-tau antibody program VY-TAU01; IND filing on track for H1 2024. SOD1 program lead candidate now expected H2 2023.

## SEC filing metadata
- accession: 0001558370-23-008652
- form_type: 8-K
- ticker: VYGR
- cik: 0001640266
- company_name: Voyager Therapeutics, Inc.
- filed_at: 2023-05-09T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1640266/000155837023008652/0001558370-23-008652-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1640266/000155837023008652/vygr-20230509x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-23-008652
- JSON: https://secwatch.observer/filing/0001558370-23-008652.json
- Plain text: https://secwatch.observer/filing/0001558370-23-008652.txt

## Key facts
- Earnings Releases
  Voyager Therapeutics, Inc. reported first quarter 2023 results: revenue $150.5 million, net income $124.0 million.
  - Period: first quarter 2023
  - Revenue: $150.5 million
  - Net income: $124.0 million
  - Result: reported results
  source text: In January 2023, Grace E. Colón, Ph.D., also joined the Board of Directors. ​ First Quarter 2023 Financial Results ● Collaboration Revenues: Voyager had collaboration revenue of $150.5 million for the first quarter of 2023, compared to $0.7 million for the same period in 2022. The increase was primarily due to revenue recognized during the first quarter of 2023 on the
  evidence_url: https://www.sec.gov/Archives/edgar/data/1640266/000155837023008652/0001558370-23-008652-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.